NAD+ is not a peptide—but every peptide vendor sells it. Dozens of human trials support the idea of raising NAD+ levels. Almost none of them studied the injectable product you're actually buying.

Nicotinamide adenine dinucleotide—NAD+—is among the most fundamental molecules in biology. It is a coenzyme required for over 500 enzymatic reactions, including glycolysis, the TCA cycle, and oxidative phosphorylation. Without it, cellular energy production stops. NAD+ also serves as the exclusive co-substrate for sirtuins, a family of seven enzymes that regulate gene expression, DNA repair, mitochondrial function, and inflammation. When NAD+ declines, sirtuin activity declines with it. This is not speculative—it is textbook biochemistry supported by thousands of published studies.

The NAD+ decline-with-aging thesis is one of the best-supported mechanisms in longevity biology. Research from labs led by David Sinclair (Harvard), Charles Brenner (City of Hope), Shin-ichiro Imai (Washington University), and Eduardo Chini (Mayo Clinic) has established that tissue NAD+ levels drop approximately 50% between ages 40 and 60. The primary culprit is CD38, a NADase enzyme that increases two- to threefold with aging. As CD38 rises and NAD+ falls, sirtuin activity drops, PARP-mediated DNA repair becomes increasingly competitive for the remaining NAD+ pool, and mitochondrial function degrades.

This much is solid. The complication is what comes next. Raising NAD+ levels in humans is possible—multiple randomized controlled trials demonstrate that oral NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) supplements increase blood NAD+ metabolites. In mice, long-term NMN supplementation extends median lifespan by 8.5% in females. But the product sold by peptide vendors as "NAD+ peptide" is not NMN or NR taken orally. It is NAD+ itself, delivered by intravenous infusion or subcutaneous injection. And for that specific product, via that specific route, the controlled human evidence is nearly nonexistent.

This article traces the full evidence chain: the biology of NAD+ decline, the precursor supplementation data, and the specific question of whether injectable NAD+—the product people are actually buying—has evidence to support it. The gap between "NAD+ matters" and "injecting NAD+ helps" is where the Dutch Uncle earns his keep.

Quick Facts: NAD+ at a Glance

What Is NAD+?

Pronunciation: en-ay-dee-plus / nad-plus

NAD+ is not new. It was discovered in 1906 by Arthur Harden and William John Young, who identified it as a factor necessary for yeast fermentation. Hans von Euler-Chelpin characterized its structure in the 1930s, earning a Nobel Prize. For most of the twentieth century, NAD+ was understood as a metabolic workhorse—an electron shuttle that carries hydrogen atoms between enzymes in the energy production chain. Important, but not exciting. Biochemistry 101.

What changed in the early 2000s was the discovery that NAD+ does more than carry electrons. In 2000, Shin-ichiro Imai and Leonard Guarente at MIT demonstrated that yeast Sir2—the founding member of the sirtuin family—requires NAD+ as an exclusive co-substrate for its enzymatic activity (PMID 10821278). No NAD+, no sirtuin activity. And sirtuins, it turned out, regulate some of the most critical processes in cellular health: DNA repair, mitochondrial biogenesis, inflammation, and gene silencing.

This discovery reframed NAD+ from a metabolic currency to a master regulator. If sirtuins are the longevity genes (a characterization that is oversimplified but directionally useful), then NAD+ is the fuel they run on. When your NAD+ levels are high, sirtuins work. When NAD+ declines—as it does with aging—sirtuin activity drops, and the cellular processes they regulate begin to fail.

Origins and Discovery

The modern NAD+ story has three acts. The first, spanning 1906 to the 1990s, established NAD+ as a metabolic coenzyme. Harden and Young discovered it. Warburg characterized its redox function. Kornberg worked out its biosynthetic pathways. For nearly a century, NAD+ was considered solved—important but unremarkable.

The second act began in 2000 with Imai and Guarente's discovery of sirtuin NAD+-dependence. By 2003, David Sinclair's lab at Harvard had shown that resveratrol activated SIRT1 (a finding later complicated by methodological controversies, but the sirtuin-longevity connection held). Sinclair became the public face of NAD+ research, writing the bestselling book Lifespan and co-founding multiple NAD+-related companies. His lab's work on NMN supplementation in mice—culminating in a 2024 study showing 8.5% median lifespan extension in female mice—has driven enormous public interest.

The third act involves Charles Brenner, who in 2004 identified nicotinamide riboside (NR) as a previously unrecognized NAD+ precursor, and demonstrated that it could raise NAD+ levels in yeast and mammalian cells. Brenner's discovery led to Tru Niagen, the first commercially available NR supplement. Meanwhile, Imai's lab at Washington University focused on NMN, demonstrating its ability to restore NAD+ levels and reverse age-related metabolic decline in mice. Eduardo Chini's group at Mayo Clinic added a critical piece in 2016 by identifying CD38 as the primary enzyme responsible for age-related NAD+ destruction.

Mechanism of Action

The NAD+ Biosynthesis Pathways

NAD+ is synthesized through three routes. The de novo pathway converts dietary tryptophan to NAD+ through a series of enzymatic steps—this is the body's backup system, accounting for only a fraction of NAD+ production. The Preiss-Handler pathway converts nicotinic acid (niacin, vitamin B3) to NAD+ via NAPRT and NMNAT enzymes. And the salvage pathway—by far the most important for maintaining NAD+ levels—recycles nicotinamide (NAM), the byproduct of sirtuin and PARP reactions, back to NAD+ through nicotinamide phosphoribosyltransferase (NAMPT → NMN → NAD+).

The salvage pathway is rate-limited by NAMPT. When NAMPT activity declines with age—and it does—the salvage pathway becomes less efficient, contributing to NAD+ decline. NMN and NR supplementation bypass this bottleneck by entering the pathway downstream of NAMPT.

The CD38 Problem

CD38 is a transmembrane glycoprotein expressed on immune cells (and increasingly on senescent cells with aging). It functions as a NADase—an enzyme that degrades NAD+. Camacho-Pereira et al. (2016, PMID 27304511) demonstrated that CD38 expression increases two- to threefold in all tissues tested during aging, and that CD38 knockout mice maintain youthful NAD+ levels. Critically, CD38 also degrades NMN—meaning that even supplemental NMN may be partially destroyed by CD38 before it can be converted to NAD+.

This has implications for NAD+ repletion strategy: boosting NAD+ may require not only supplementing precursors but also inhibiting CD38. Flavonoids like apigenin, quercetin, and the synthetic compound 78c have shown CD38-inhibitory activity in preclinical models.

The Sirtuin Network

Seven sirtuins (SIRT1–7) operate in different cellular compartments: - SIRT1 (nucleus): Gene silencing, DNA repair, inflammation suppression. The most studied longevity-associated sirtuin. - SIRT3 (mitochondria): Oxidative stress defense, fatty acid oxidation. Directly regulated by NAD+ via CD38/SIRT3 axis (Camacho-Pereira 2016). - SIRT6 (nucleus): Telomere maintenance, DNA double-strand break repair. Overexpression extends mouse lifespan. - Others: SIRT2 (cytoplasm, cell cycle), SIRT4/5 (mitochondria, metabolic regulation), SIRT7 (nucleolus, ribosome biogenesis).

All seven require NAD+ as a co-substrate. The stoichiometry matters: each deacylation reaction consumes one molecule of NAD+ and produces one molecule of nicotinamide (which feeds back into the salvage pathway). This means sirtuin activity is directly coupled to NAD+ availability.

The PARP Competition

PARPs (PARP1, PARP2) are DNA repair enzymes that also consume NAD+—and they consume far more per activation event than sirtuins. A single PARP1 activation during DNA damage can consume 100+ NAD+ molecules. In aging, chronic low-level DNA damage leads to chronically elevated PARP activity, which depletes NAD+ pools and starves sirtuins. This PARP-sirtuin competition for a shrinking NAD+ pool is a central mechanism in the NAD+ theory of aging (Gomes et al., 2013, PMID 24360282).

Key Research Areas and Studies

NAD+ Precursor Trials in Humans

The strongest evidence for NAD+ repletion comes from oral precursor studies. Key trials:

NMN—Muscle and Metabolic Function (Yoshino et al., 2021, PMID 34862480): 25 prediabetic postmenopausal women received NMN (250 mg/day) or placebo for 10 weeks. NMN increased muscle insulin sensitivity and improved muscle remodeling gene expression. No change in body weight. First RCT demonstrating a metabolic benefit of NMN in humans.

NMN—Aerobic Capacity (Liao et al., 2021, PMID 34238308): 48 amateur runners were randomized to NMN (300, 600, or 1200 mg/day) or placebo for 6 weeks. NMN dose-dependently improved aerobic capacity and ventilatory threshold. Suggests enhanced skeletal muscle oxygen utilization.

NMN—Muscle Function in Older Men (Igarashi et al., 2022, PMID 35441939): 42 older men received NMN (250 mg/day) or placebo for 6–12 weeks. Blood NAD+ metabolites increased. Gait speed and grip strength partly improved. Chronic oral NMN was well tolerated.

NR—Cardiovascular (Martens et al., 2018, PMID 29599478): 24 healthy older adults received NR (1000 mg/day) or placebo in crossover design × 6 weeks. NR raised NAD+ metabolites ~60% in PBMCs. Trend toward reduced aortic stiffness and systolic blood pressure.

NR—Parkinson's Disease (Brakedal et al., 2022, PMID 35504280): 30 PD patients received NR (1000 mg) or placebo × 30 days. Blood NAD+ increased. Mild improvement in MDS-UPDRS scores. Cerebral metabolic changes on MRI. Small and short but neurologically interesting.

NR—Long-COVID (De Laat et al., 2025): 58 patients received NR (2000 mg/day) or placebo × 24 weeks. NAD+ levels rose. No significant improvement in cognition or symptom recovery. Negative trial at the highest dose tested to date.

Null Results—Important: Dollerup et al. (2018, PMID 29992272): NR in obese men showed no insulin sensitivity improvement. Remie et al. (2020, PMID 33095781): NR in obese adults showed no insulin sensitivity improvement. These null results are important—NAD+ repletion does not universally translate to metabolic benefit.

Injectable NAD+—The Thin Evidence

Grant et al. (2024, medRxiv preprint—NOT PEER-REVIEWED): 28 healthy adults randomized to IV NAD+ (500 mg), IV NR (500 mg), oral NR (500 mg), or saline placebo. All active arms raised blood NAD+. NAD+ IV caused significantly more side effects than NR IV (nausea, headache, diarrhea, muscle tightness). No liver enzyme abnormalities at 30 days. This is the only controlled study comparing IV NAD+ to anything. It is a preprint.

Retrospective Chart Review (Frontiers in Aging, 2026): ~200 patients receiving IV NAD+ or IV NR at a wellness clinic. Both tolerable. NAD+ IV associated with more infusion-related side effects. Not a controlled trial. Selection bias inherent.

Animal Lifespan Data

Kane et al. (2024, PMID 38979132): Long-term NMN treatment in naturally aging mice (Harvard/Sinclair). NMN increased median lifespan 8.5% in female mice and delayed frailty onset in both sexes. Male mice showed metabolic benefits but no lifespan extension. Sex-dependent effect—NMN metabolism was greater in females.

Mills et al. (2016, PMID 27127236): NMN (300 mg/kg/day × 12 months) in aged mice suppressed weight gain, enhanced insulin sensitivity, improved physical activity, eye function, and mitochondrial metabolism. The landmark "NMN works in mice" paper.

Claims vs. Evidence

The Human Evidence Landscape

The human evidence for NAD+ repletion is a study in mismatch. Oral precursors (NMN, NR) have been tested in at least 15 randomized controlled trials totaling over 750 participants. These trials consistently show that oral NAD+ precursors raise blood NAD+ metabolites. What they do not consistently show is downstream clinical benefit. Metabolic improvements appear in some trials (insulin sensitivity in prediabetic women, aerobic capacity in runners) but not others (no insulin benefit in obese men, no cognitive benefit in long-COVID). The pattern suggests that NAD+ repletion may benefit specific populations and tissues but is not a universal intervention.

For injectable NAD+—the product peptide vendors actually sell—the controlled human evidence consists of a single preprint comparing one 500 mg IV dose to controls. That study was designed for tolerability and acute NAD+ kinetics, not clinical outcomes. No controlled trial has examined repeated IV NAD+ infusions. No controlled trial has examined subcutaneous NAD+. The entire evidence base for injectable NAD+ in humans is weaker than the evidence for BPC-157, and BPC-157 is a Tier 3 compound on Peptidings.

This creates a peculiar situation: one of the best-studied molecules in longevity biology (NAD+) is sold through one of the least-studied routes (injection) as a product with essentially no product-specific evidence. The science is strong. The product is not the science.

Safety, Risks, and Limitations

NMN/NR Oral Safety (Good Data)

• Well tolerated in all published RCTs at doses up to 1200 mg/day (NMN) and 2000 mg/day (NR) for up to 24 weeks.
• NR has FDA GRAS status. No hepatotoxicity, no flushing (unlike niacin).
• Most common side effects: mild GI symptoms (nausea, bloating) in some participants.
• Long-term safety (>1 year) in humans has not been established.
• NMN single-dose safety confirmed at 100–500 mg (no vital sign changes).

IV NAD+ Safety (Limited Data, Concerning Signals)

• Pilot data: Majority of participants reported adverse effects during IV NAD+ infusion—nausea, headache, diarrhea, muscle tightness. These were infusion-rate-dependent and resolved after infusion.
• No serious adverse events in published reports at standard clinical doses (250–1000 mg).
• IV NR was significantly better tolerated than IV NAD+ in the only head-to-head study.
• No PK data for IV NAD+ exists. Elimination kinetics, tissue distribution, and dose-response remain unstudied in controlled settings.

Subcutaneous NAD+ Safety (No Data)

• No published safety data exists for subcutaneous NAD+ injection.
• Community reports: injection site pain/stinging (NAD+ is acidic in solution), transient nausea, flushing.
• Absence of reported adverse events in self-experimentation communities does not constitute safety data.

Theoretical Concerns

• Cancer risk: NAD+ fuels both sirtuin activity (generally protective) and cancer cell metabolism. Raising NAD+ in someone with undiagnosed cancer could theoretically support tumor growth. No clinical evidence of increased cancer risk from NAD+ supplementation, but no long-term studies have looked for it.
• PARP fueling: In the context of chronic DNA damage, additional NAD+ could increase PARP activity and inflammation. Unknown clinical significance.
• Product quality: Third-party testing reveals widespread quality problems in commercial NMN/NAD+ products—underdosing, mislabeling, contamination. Injectable NAD+ from gray-market vendors carries additional sterility and purity risks.

Legal and Regulatory Status

NAD+ itself has no FDA approval as a drug. It occupies a regulatory gray zone: not explicitly prohibited for compounding, but not on the FDA's approved list for sterile injectables either. NR has GRAS status for oral supplementation (Tru Niagen). NMN's status was contested from 2022 to 2025—the FDA initially excluded it from the dietary supplement definition under DSHEA's drug preclusion provision (because it was being investigated as a drug under an IND). After legal pressure from the Natural Products Association and Alliance for Natural Health, the FDA reversed this decision in September 2025, reinstating NMN as a lawful dietary supplement with New Dietary Ingredient notification requirements.

Injectable NAD+ is available from compounding pharmacies (both 503A and 503B), IV wellness clinics, and gray-market peptide vendors. It is not FDA-approved for any indication. WADA does not prohibit NAD+ or any of its precursors.

Research Protocols and Laboratory Practices

NAD+ is water-soluble and stable in lyophilized form. Reconstituted solutions should be stored at 2–8°C (35–46°F) and used within the timeframe specified by the manufacturer. IV infusions are typically administered over 2–8 hours at clinical settings to manage infusion-rate-dependent side effects. Subcutaneous injections are self-administered at home using insulin syringes. No published protocol exists for subcutaneous administration.

Dosing in Published Research

NAD+ precursor dosing in published research spans a wider range than most compounds covered on this site—primarily because NAD+ is not a single molecule but a metabolic target approached through multiple precursors (NMN, NR, direct NAD+) and routes (oral, IV, subcutaneous). The table below summarizes dosing from controlled or semi-controlled human studies only. Animal data and uncontrolled case series are excluded.

Dosing in Independent Self-Experimentation Communities

The following table summarizes community-reported dosing practices for NAD+. These are not clinical recommendations. No controlled trial data supports these protocols.

[WHY NEARLY EMPTY—Gold callout]: Published research on injectable NAD+ is almost entirely limited to IV infusions studied for addiction recovery (uncontrolled case series), acute tolerability (one small preprint), and retrospective chart reviews. No controlled trial has established dosing parameters for injectable NAD+ at any route. Every subcutaneous and most IV community protocols are extrapolated from clinical anecdote, not published research. The NMN/NR oral dosing column is better supported because multiple RCTs exist—but even there, optimal dose and duration are not established.

Combination Stacks

Research into NAD+ combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining NAD+ with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

NAD+ is one of the most important molecules in your body, and its decline with aging is one of the most well-supported mechanisms in longevity science. The biology is real. The sirtuins are real. CD38-mediated NAD+ destruction is real. The question is not whether NAD+ matters—it does. The question is whether the products available to consumers effectively address the decline.

What the evidence supports: - Oral NMN and NR supplements raise blood NAD+ metabolites in humans (multiple RCTs). - NMN extended lifespan in female mice by 8.5% (one study, 2024). - NMN improved aerobic capacity in runners and insulin sensitivity in prediabetic women (individual RCTs). - Oral precursors are well tolerated at published doses.

What the evidence does not support: - That injectable NAD+ is superior to oral precursors (untested). - That subcutaneous NAD+ is effective for any endpoint (zero published data). - That NAD+ supplementation reverses aging in humans (no trial has tested this). - That IV NAD+ treats addiction (no controlled trial). - That the benefits seen in mice will translate to humans at the same magnitude.

The honest assessment: If you want to boost NAD+ levels, the evidence supports oral NMN or NR—not because they've been proven to extend human lifespan, but because they've been shown to raise NAD+ and are well tolerated. If you're injecting "NAD+ peptide" subcutaneously, you are using a product with no published evidence for that route. The molecule is real. The injection is a bet.

Verdict Recapitulation

NAD+ Peptide carries an Evidence Tier of ~—It's Complicated, reflecting the split between robust oral-precursor RCT data (Tier 2) and near-zero injectable evidence (Tier 3–4). The overall verdict is Eyes Open: the biology is strong, oral precursors are well-supported, but injectable NAD+ products lack the controlled human data needed to justify the cost, pain, and risk.

For readers considering NAD+, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source NAD+

Further Reading and Resources

If you want to go deeper on NAD+, the evidence landscape for longevity & anti-aging peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Longevity & Anti-Aging Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: NAD+ — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Imai S, et al. (2000). Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. PMID 10821278
2. Camacho-Pereira J, et al. (2016). CD38 dictates age-related NAD decline and mitochondrial dysfunction through a SIRT3-dependent mechanism. Cell Metabolism. PMID 27304511
3. Mills KF, et al. (2016). Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metabolism. PMID 27127236
4. Gomes AP, et al. (2013). Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. PMID 24360282
5. Martens CR, et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. PMID 29599478
6. Yoshino M, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. PMID 34862480
7. Liao B, et al. (2021). Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners. Journal of the International Society of Sports Nutrition. PMID 34238308
8. Igarashi M, et al. (2022). Chronic nicotinamide mononucleotide supplementation elevates blood NAD+ levels and alters muscle function in healthy older men. npj Aging. PMID 35441939
9. Brakedal B, et al. (2022). The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metabolism. PMID 35504280
10. Kane AE, et al. (2024). Long-term NMN treatment increases lifespan and healthspan in mice in a sex-dependent manner. Cell Metabolism. PMID 38979132
11. Verdin E. (2014). NAD+ in aging, metabolism, and neurodegeneration. Science. PMID 24954210
12. Xie N, et al. (2024). Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review. American Journal of Physiology. PMID 37971292
13. De Laat SC, et al. (2025). Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. eClinicalMedicine / The Lancet
14. Grant R, et al. (2024). Randomized, placebo-controlled, pilot clinical study evaluating acute Niagen+ IV and NAD+ IV in healthy adults. medRxiv (preprint, not peer-reviewed)
15. Dollerup OL, et al. (2018). A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men. Journal of Clinical Endocrinology & Metabolism. PMID 29992272
16. Yoshino J, et al. (2011). Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metabolism. PMID 22010179

---